非维生素K拮抗剂口服抗凝药治疗期间发生急性卒中的心房颤动患者中复发性缺血性卒中与出血:RENO-EXTEND研究
这项前瞻性多中心观察研究纳入在心房颤动患者中,于非维生素K拮抗剂口服抗凝药治疗期间发生急性脑血管缺血事件后的连续病例,估算随访期间缺血与出血事件发生率及其决定因素,并比较更换抗凝药与继续原治疗两组的事件风险。平均随访15.0±10.9个月,1240例中192例(15.5%)发生207次缺血或出血事件,年发生率为13.4%。结论认为此类患者复发缺血性卒中与出血风险高,需进一步研究以改善二级预防。
要点
- 平均随访15.0±10.9个月,1240例中192例(15.5%)发生207次缺血或出血事件,年发生率13.4%。
- 复发缺血事件预测因素包括指数事件后CHA2DS2-VASc评分(OR 1.2,95%CI 1.0-1.3,P=0.05)与高血压(OR 2.3,95%CI 1.0-5.1,P=0.04)。
- 出血事件预测因素包括年龄(OR 1.1,95%CI 1.0-1.2,P=0.002)、大出血史(OR 6.9,95%CI 3.4-14.2,P=0.0001)与联用抗血小板药(OR 2.8,95%CI 1.4-5.5,P=0.003)。
核心结论
- 在接受非维生素K拮抗剂口服抗凝药治疗期间仍发生卒中的患者,复发缺血性卒中与出血风险高。
- 作者认为需进一步研究,通过探究复发性缺血性卒中与出血的机制来改善二级预防。
研究设计与样本
- 前瞻性多中心观察研究,纳入在心房颤动患者中于非维生素K拮抗剂口服抗凝药治疗期间发生急性脑血管缺血事件的连续病例。
- 估算随访期间缺血与出血事件发生率及其决定因素,并比较更换抗凝药与继续原治疗两组的事件风险。
主要发现
- 平均随访15.0±10.9个月,1240例中192例(15.5%)发生207次缺血或出血事件,年发生率为13.4%。
- 事件包括缺血性卒中111次、系统性栓塞15次、颅内出血24次、重大颅外出血57次。
- 复发缺血事件(卒中与系统性栓塞)预测因素:指数事件后CHA2DS2-VASc评分每增加1分OR 1.2(95%CI 1.0-1.3,P=0.05);高血压OR 2.3(95%CI 1.0-5.1,P=0.04)。
- 出血事件(颅内与重大颅外出血)预测因素:年龄每增加1岁OR 1.1(95%CI 1.0-1.2,P=0.002);大出血史OR 6.9(95%CI 3.4-14.2,P=0.0001);联用抗血小板药OR 2.8(95%CI 1.4-5.5,P=0.003)。
- 更换与未更换原非维生素K拮抗剂口服抗凝药治疗的患者缺血与出血事件发生率无差异(OR 1.2,95%CI 0.8-1.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with atrial fibrillation who suffered an ischemic stroke while on treatment with nonvitamin K antagonist oral anticoagulants, rates and determinants of recurrent ischemic events and major bleedings remain uncertain. METHODS: This prospective multicenter observational study aimed to estimate the rates of ischemic and bleeding events and their determinants in the follow-up of consecutive patients with atrial fibrillation who suffered an acute cerebrovascular ischemic event while on nonvitamin K antagonist oral anticoagulant treatment. Afterwards, we compared the estimated risks of ischemic and bleeding events between the patients in whom anticoagulant therapy was changed to those who continued the original treatment. RESULTS: After a mean follow-up time of 15.0±10.9 months, 192 out of 1240 patients (15.5%) had 207 ischemic or bleeding events corresponding to an annual rate of 13.4%. Among the events, 111 were ischemic strokes, 15 systemic embolisms, 24 intracranial bleedings, and 57 major extracranial bleedings. Predictive factors of recurrent ischemic events (strokes and systemic embolisms) included CHA2DS2-VASc score after the index event (odds ratio [OR], 1.2 [95% CI, 1.0-1.3] for each point increase; P=0.05) and hypertension (OR, 2.3 [95% CI, 1.0-5.1]; P=0.04). Predictive factors of bleeding events (intracranial and major extracranial bleedings) included age (OR, 1.1 [95% CI, 1.0-1.2] for each year increase; P=0.002), history of major bleeding (OR, 6.9 [95% CI, 3.4-14.2]; P=0.0001) and the concomitant administration of an antiplatelet agent (OR, 2.8 [95% CI, 1.4-5.5]; P=0.003). Rates of ischemic and bleeding events were no different in patients who changed or not changed the original nonvitamin K antagonist oral anticoagulants treatment (OR, 1.2 [95% CI, 0.8-1.7]). CONCLUSIONS: Patients suffering a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are at high risk of recurrent ischemic stroke and bleeding. In these patients, further research is needed to improve secondary prevention by investigating the mechanisms of recurrent ischemic stroke and bleeding.
引用
- Paciaroni M, Caso V, Agnelli G, et al. Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke. 2022. PMID: 35543133. doi:10.1161/STROKEAHA.121.038239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。